CME Presentations




  • Emmanuel Mignot, MD, PhD

    Emmanuel Mignot, MD, PhD

    Emmanuel Mignot, MD, PhD

    Craig Reynolds Professor of Sleep Medicine

    Emmanuel Mignot, MD, PhD, is the Craig Reynolds Professor of Sleep Medicine. He discovered that human narcolepsy is caused by the autoimmune loss of ~20,000 hypothalamic neurons secreting the wake-promoting peptide hypocretin. Dr. Mignot identified HLA-DQB1*06:02 and T-Cell receptor genes as major susceptibility genes across ethnic groups, which act together to promote a highly selective T cell mediated autoimmune process triggered by influenza infection. He has received numerous awards and is a member of the National Academies of Sciences and Medicine. Applying lessons learned from narcolepsy immunogenetics, Dr. Mignot has found a protective signal in an immune gene called HLA-DR, specifically the presence of the HLA-DRB1*04 (DR4) subtype in Parkinson’s disease (PD).
  • Michael Thorpy, MBChB

    Michael Thorpy, MBChB

CME Information

Global Logo PQH Logo

Emerging Approaches and Patient‐centered Care for Narcolepsy

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Sleep Association (ASA).


This activity is supported by an educational grant from Avadel Pharmaceuticals.


This activity was released on December 13, 2021 and is valid until December 13, 2022. Requests for credit must be made no later than December 13, 2022.


The primary target audiences for the HCP activity are neurologists, sleep specialists, and specialty NPs and PAs. Secondary audiences include primary care physicians, internists, advanced practitioners, pharmacists, and nurses


Narcolepsy is a chronic neurologic disorder characterized by excessive daytime sleepiness (EDS), sleep paralysis, hypnagogic and hypnopompic hallucinations, disrupted nocturnal sleep, dysregulated rapid eye movement (REM) sleep, and cataplexy in most patients. Despite these obvious symptoms, narcolepsy is often under‐recognized, with diagnostic delays of up to 15 years, or misdiagnosed, depriving patients of appropriate treatment and care. However, if diagnosed accurately, emerging agents for narcolepsy could provide a new, patient‐centered management option.

Join a panel of expert clinicians and patient representatives for an in-depth discussion of the shifting standards of care for narcolepsy with or without cataplexy. Panelists will discuss strategies to address barriers to the recognition of the disorder and detail assessment tools and methods to ensure an accurate and timely diagnosis. In addition, the education will explore highly anticipated upcoming and more patient centered agents, indications, and classes of agents that are expected to further refine the narcolepsy treatment armamentarium.

Do you have patients who could benefit from related education on the recognition and care of narcolepsy? Direct your patients to to access the related patient-education activity, “More than Sleepiness: How Recognizing and Treating Narcolepsy Will Impact the Entire Family.”


After completing this activity, the participant should be better able to:
  • Describe signs and symptoms that support a suspicion of narcolepsy with/without cataplexy
  • Formulate a differential diagnosis for narcolepsy with/without cataplexy
  • Describe the adverse effects of EDS and interrupted sleep on patient QoL and overall health
  • Assess the safety, efficacy, and tolerability profiles of available and investigational therapies for the treatment of narcolepsy with/without cataplexy


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Emmanuel Mignot, MD, PhD
Craig Reynolds Professor of Sleep Medicine
Stanford University
Consulting Fee: Centessa Pharmaceuticals, Eisai Pharmaceuticals , Inexia, Jazz Pharmaceuticals, Takeda Pharmaceuticals
Stock Shareholder: Centessa Pharmaceuticals
Other (Describe): Idorsia - coauthor helping to write a publication, but this does not involve any financial agreement.
Michael Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine
Consulting Fee: Axsome, Balance Therapeutics, Flamel/Avadel, Harmony Biosciences, LLC, Jazz Pharmaceuticals, Suven Life Sciences Ltd., Takeda Pharmaceutical Co., Ltd, NLS Pharmaceuticals and Eisai Pharmaceuticals

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Kim Rodriguez Nothing to disclose
Carole Drexel Nothing to disclose
Eve Wilson Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at